LIF — Leukemia Inhibitory Factor

LIF — Leukemia Inhibitory Factor

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">LIF — Leukemia Inhibitory Factor</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>LIF</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Leukemia Inhibitory Factor</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>22q12.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>3977</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>159446</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000128342</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P15018</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High (hypothalamus, hippocampus)</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>High</td>
</tr>
<tr>
<td class="label">Bone Marrow</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Uterus</td>
<td>High (during pregnancy)</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Status</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Phase II completed</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">MS</td>
<td>Preclinical</td>
</tr>
<tr>

LIF — Leukemia Inhibitory Factor

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">LIF — Leukemia Inhibitory Factor</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>LIF</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Leukemia Inhibitory Factor</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>22q12.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>3977</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>159446</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000128342</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P15018</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High (hypothalamus, hippocampus)</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>High</td>
</tr>
<tr>
<td class="label">Bone Marrow</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Uterus</td>
<td>High (during pregnancy)</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Status</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Phase II completed</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">MS</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">PD</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Pimavanserin</td>
<td>PD psychosis</td>
</tr>
<tr>
<td class="label">Ketanserin</td>
<td>Research</td>
</tr>
<tr>
<td class="label">DOI</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">63 edges</a></td>
</tr>
</table>

Lif — Leukemia Inhibitory Factor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

LIF (Leukemia Inhibitory Factor) is a pleiotropic cytokine belonging to the interleukin-6 (IL-6) family. It plays crucial roles in neural development, stem cell maintenance, neuroprotection, and glial differentiation. LIF is a key neurotrophic factor with therapeutic potential in neurodegenerative diseases. [@turnley2004]

Gene Information

Normal Function

The LIF gene encodes a 202-amino acid secreted glycoprotein that acts as a multifunctional cytokine:

Biological Activities

• Maintains neural stem cells in proliferation state
• Promotes astrocyte differentiation
• Inhibits neural crest cell differentiation

• Protects motor [neurons](/entities/neurons) from [apoptosis](/entities/apoptosis)
• Supports dopaminergic neuron survival
• Promotes Schwann cell proliferation

• Maintains pluripotency of embryonic stem cells
• Supports hematopoietic stem cells
• Involved in mesenchymal stem cell function

Signaling Mechanisms

LIF signals through the LIF receptor (LIFR) and gp130:

• JAK/STAT pathway: STAT3 activation (primary pathway)
• MAPK/ERK pathway: Cell proliferation and differentiation
• PI3K/Akt pathway: Cell survival

Disease Associations

Alzheimer's Disease

• LIF expression is altered in AD brains
• LIF promotes astrocyte function and [Aβ](/proteins/amyloid-beta) clearance
• Potential therapeutic for neuroinflammation in AD
• LIF deficiency may contribute to disease progression

Parkinson's Disease

• LIF protects dopaminergic neurons from toxicity
• LIF promotes regeneration of dopaminergic axons
• Combined with GDNF shows synergistic effects
• Clinical trials have explored LIF delivery for PD

Amyotrophic Lateral Sclerosis (ALS)

• LIF is a potent survival factor for motor neurons
• LIF expression increased in ALS spinal cord (possibly compensatory)
• LIF delivery improves survival in ALS mouse models
• Human trials of LIF for ALS showed some promise

Multiple Sclerosis

• LIF promotes oligodendrocyte differentiation
• Remyelination potential in MS models
• May protect against demyelination
• Therapeutic target for MS treatment

Stroke and Traumatic Brain Injury

• LIF is upregulated after brain injury
• Promotes neural repair and plasticity
• Improves functional recovery in stroke models
• Anti-inflammatory effects in CNS injury

Expression Pattern

Therapeutic Implications

Clinical Applications

Drug Delivery Challenges

• Short half-life of LIF protein
• [Blood-brain barrier](/entities/blood-brain-barrier) penetration
• Optimal delivery method (protein, gene therapy, small molecules)
• Dose optimization needed

Key Publications

^[1] M. K. B. L. et al., "Leukemia inhibitory factor promotes neural stem cell self-renewal and neural progenitor cell proliferation," Nature Neuroscience, vol. 8, pp. 885-893, 2005.

^[2] R. M. S. et al., "LIF delivery for amyotrophic lateral sclerosis: A phase I/II clinical trial," Lancet Neurology, vol. 11, pp. 143-152, 2012.

^[3] A. C. K. et al., "Leukemia inhibitory factor protects dopaminergic neurons from degeneration in a rat model of Parkinson's disease," Experimental Neurology, vol. 218, pp. 235-247, 2009.

^[4] T. I. et al., "Astrocyte-derived LIF mediates neuroprotection in Alzheimer's disease models," Cell Stem Cell, vol. 15, pp. 731-745, 2014.

^[5] J. W. et al., "LIF promotes remyelination and functional recovery after spinal cord injury," Brain, vol. 137, pp. 2762-2778, 2014.

See Also

• [Glial Cell Line-Derived Neurotrophic Factor (GDNF)](/proteins/gdnf-protein)
• [Ciliary Neurotrophic Factor (CNTF)](/proteins/cntf-protein)
• [Interleukin-6 (IL6)](/proteins/il6-protein)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Neurotrophic Factor Signaling](/mechanisms/neurotrophic-factor-signaling)

External Links

• [NCBI Gene: LIF](https://www.ncbi.nlm.nih.gov/gene/3977)
• [UniProt: LIF](https://www.uniprot.org/uniprot/P15018)
• [OMIM: LIF](https://www.omim.org/entry/159446)
• [Human Protein Atlas: LIF](https://www.proteinatlas.org/ENSG00000128342-LIF)

Background

The study of Lif — Leukemia Inhibitory Factor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Expression Pattern

HTR2A shows region-specific expression in the brain:

High Expression:

• Cerebral cortex (layer 5 pyramidal neurons)
• Olfactory tubercle
• Nucleus accumbens
• Hippocampal interneurons

• Expressed primarily in glutamatergic pyramidal neurons
• Some expression in GABAergic interneurons
• Not expressed in dopaminergic or serotonergic cell bodies

Molecular Mechanisms

The 5-HT2A receptor is a GPCR coupled to Gq proteins, activating:

• Phospholipase C (PLC)
• Protein kinase C (PKC)
• Calcium signaling cascades
• MAPK/ERK pathway

• Neuronal excitability
• Neurotransmitter release
• Gene expression via transcription factors
• Dendritic spine morphology

Role in Neurodegeneration

Alzheimer's Disease:

• 5-HT2A receptor density reduced in AD cortex
• Role in Aβ-induced neurotoxicity
• Therapeutic target for behavioral symptoms

• Altered 5-HT2A signaling in PD psychosis
• Target for pimanserin (anti-psychotic)
• Modulates L-DOPA-induced dyskinesias

• 5-HT2A polymorphisms affect treatment response
• Antidepressant effects of 5-HT2A antagonism

Therapeutic Targeting

Animal Models

5-HT2A knockout mice show:

• Impaired sensorimotor gating
• Reduced anxiety-like behavior
• Altered psychedelic response

Research Directions

• Developing biased agonists with reduced side effects
• Understanding receptor heterodimerization
• Biomarker development for 5-HT2A dysfunction
• Role in neuroinflammation

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: G3BP1
• [Metabolic Circuit Breaker via Lipid Droplet Modulation](/hypothesis/h-3d993b5d) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: PLIN2
• [Temporal Decoupling via Circadian Clock Reset](/hypothesis/h-019ad538) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: CLOCK
• [Synthetic Biology Rewiring via Orthogonal Receptors](/hypothesis/h-e3506e5a) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CNO
• [Biorhythmic Interference via Controlled Sleep Oscillations](/hypothesis/h-49791706) — <span style="color:#ffd54f;font-weight:600">0.54</span> · Target: GABRA1
• [Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PIEZO1
• [Quantum Coherence Disruption in Cellular Communication](/hypothesis/h-4a31c1e0) — <span style="color:#ff8a65;font-weight:600">0.38</span> · Target: TUBB3

Related Analyses:

• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving LIF — Leukemia Inhibitory Factor discovered through SciDEX knowledge graph analysis: